SCHEMBL27052202

SCHEMBL27052202

CC1CCC2C(C1)C1OC2C(OC(=O)c2ccccc2)C1OC(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APOBEC3A P31941 1/20 0.45
▸ APOBEC3G Q9HC16 1/20 0.45
▸ CHRNA7 P36544 3/20 0.43
▸ HTR3E A5X5Y0 1/20 0.43
▸ HTR3B O95264 1/20 0.43
▸ HTR3A P46098 1/20 0.43
▸ HTR3D Q70Z44 1/20 0.43
▸ HTR3C Q8WXA8 1/20 0.43
▸ STAT3 P40763 1/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ LGALS9 O00182 1/20 0.41
▸ LGALS1 P09382 1/20 0.41
▸ LGALS3 P17931 1/20 0.41
▸ LGALS7; LGALS7B P47929 1/20 0.41
▸ CHRM2 P08172 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27052553 0.92 APOBEC3A (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052206 0.86 APOBEC3A (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052205 0.84 MAPT (0.42) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052546 0.83 LGALS9 (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052194 0.83 LGALS9 (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052180 0.82 CHRNA7 (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052552 0.82 APOBEC3A (0.42) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052555 0.80 SLC18A3 (0.43) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27055985 0.79 CHRNA7 (0.48) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B
SCHEMBL27052557 0.78 APOBEC3A (0.46) APOBEC3AAPOBEC3GCHRNA7HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067763-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 — — US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025838-A1 ESTER COMPOUND NR1H3, CYP4A11, H1-4 APOBEC3A 3887/4885APOBEC3G 4007/4885CHRNA7 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback